POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.

Maryland Bill Requires Insurers to Cover Long-Term Antibiotic Treatment for Lyme Disease

Original title: Health Insurance - Lyme Disease and Related Tick-Borne Illnesses - Long-Term Antibiotic Treatment

Last action · March 6, 2026: Hearing 3/13 at 1:00 p.m.Sponsor: Johnny Mautz

Companion · HB 1375same policy, House version
Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

Maryland health insurers, nonprofit health service plans, and health maintenance organizations must provide coverage for the full duration of s prescribed by a licensed physician for Lyme disease and related tick-borne illnesses, starting January 1, 2027.

Why it matters

Patients undergoing extended antibiotic therapy for tick-borne infections gain mandated insurance protection against coverage caps and denials based on experimental treatment labels.

Background
  • Lyme disease is a tick-borne bacterial infection transmitted by blacklegged ticks carrying Borrelia burgdorferi, which can result in chronic symptoms for some patients requiring extended medical management. context
  • State-level health insurance mandates establish minimum coverage requirements that commercial health insurance plans operating within the state jurisdiction must incorporate into their benefit packages. context

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Insurers and nonprofit health service plans

Must provide coverage for the full length of long-term antibiotic treatments prescribed for Lyme disease and related tick-borne illnesses without quantitative limits or experimental exclusions.

Directly affected

Health maintenance organizations

Must provide coverage for the full length of long-term antibiotic treatments prescribed for Lyme disease and related tick-borne illnesses without quantitative limits or experimental exclusions.

Directly affected

Licensed physicians

Can order long-term antibiotic treatments for therapeutic purposes that insurers are legally required to cover for their patients.

Directly affected

Patients with Lyme disease and related tick-borne illnesses

Gain guaranteed insurance coverage for long-term antibiotic treatments exceeding 4 weeks without quantitative limits or denials based on experimental status.

Key Facts

  • Applies to insurers and nonprofit health service plans providing hospital, medical, surgical, or pharmaceutical benefits under policies issued or delivered in Maryland.
  • Applies to health maintenance organizations providing hospital, medical, surgical, or pharmaceutical benefits under contracts issued or delivered in Maryland.
  • Requires coverage for the full length of long-term antibiotic treatment when ordered by a licensed treating physician for therapeutic purposes.
  • Prohibits insurers, nonprofit health service plans, and health maintenance organizations from imposing quantitative limitations on long-term antibiotic treatments.
Show all 10 facts
  • Prohibits entities from denying coverage solely because a treatment is categorized as unproven, experimental, or investigational.
  • Defines long-term antibiotic treatment as oral, intramuscular, or intravenous antibiotic medications administered for longer than 4 weeks.
  • Includes within the definition of Lyme disease clinical diagnoses based on signs or symptoms of acute infection, late-stage or chronic infection, complications, CDC-recognized strains, CDC surveillance criteria, or clinical diagnoses by a licensed physician using medical history, physical examinations, or supportive testing data.
  • Includes related tick-borne illnesses such as bartonellosis, babesiosis, ehrlichiosis, anaplasmosis, piroplasmosis, and other associated illnesses.
  • Applies to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2027.
  • Takes effect January 1, 2027.

Frequently Asked Questions

What types of insurance plans are covered under this bill?
The bill applies to insurers and nonprofit health service plans providing hospital, medical, surgical, or pharmaceutical benefits on an expense-incurred basis, as well as health maintenance organizations operating under contracts issued or delivered in Maryland.
Can insurers deny coverage by claiming long-term antibiotic treatment is experimental?
No. An entity subject to this section may not deny coverage for otherwise eligible treatment solely because the treatment may be categorized as unproven, experimental, or investigational in nature.
What is considered long-term antibiotic treatment under the legislation?
means the administration of oral, intramuscular, or intravenous antibiotic medications for longer than 4 weeks, including separate and combination administrations.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

3 actions
  1. Mar 6, 2026Senate
    Hearing 3/13 at 1:00 p.m.
  2. Mar 4, 2026SenateCommittee
    Rereferred to Finance
  3. Feb 13, 2026SenateIntroduced
    First Reading Senate Rules

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift98% confidence

Prohibition of Experimental Classification Denials

The bill explicitly forbids insurers from denying coverage for long-term tick-borne illness treatments on the basis that they are experimental or investigational.

Connected Entities

Centers for Disease Control and Prevention, Borrelia burgdorferi, Johnny Mautz
OrganizationCenters for Disease Control and Prevention“Federal agency that sets surveillance criteria and identifies strains causing Ly”Map →
otherBorrelia burgdorferi“Bacterium causing Lyme disease”Map →
PersonJohnny Mautz“Senator who introduced Senate Bill 969”Map →

Sources

Open source document

mgaleg.maryland.gov

Analysis Score

0–100
  • Significance65
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record